302 related articles for article (PubMed ID: 30013764)
1. The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia.
Abou Dalle I; DiNardo CD
Ther Adv Hematol; 2018 Jul; 9(7):163-173. PubMed ID: 30013764
[TBL] [Abstract][Full Text] [Related]
2. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
Stein EM; Fathi AT; DiNardo CD; Pollyea DA; Roboz GJ; Collins R; Sekeres MA; Stone RM; Attar EC; Frattini MG; Tosolini A; Xu Q; See WL; MacBeth KJ; de Botton S; Tallman MS; Kantarjian HM
Lancet Haematol; 2020 Apr; 7(4):e309-e319. PubMed ID: 32145771
[TBL] [Abstract][Full Text] [Related]
3. Enasidenib in mutant
Stein EM; DiNardo CD; Pollyea DA; Fathi AT; Roboz GJ; Altman JK; Stone RM; DeAngelo DJ; Levine RL; Flinn IW; Kantarjian HM; Collins R; Patel MR; Frankel AE; Stein A; Sekeres MA; Swords RT; Medeiros BC; Willekens C; Vyas P; Tosolini A; Xu Q; Knight RD; Yen KE; Agresta S; de Botton S; Tallman MS
Blood; 2017 Aug; 130(6):722-731. PubMed ID: 28588020
[TBL] [Abstract][Full Text] [Related]
4. Enasidenib.
Krämer A; Bochtler T
Recent Results Cancer Res; 2018; 212():187-197. PubMed ID: 30069631
[TBL] [Abstract][Full Text] [Related]
5. Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
Fathi AT; DiNardo CD; Kline I; Kenvin L; Gupta I; Attar EC; Stein EM; de Botton S;
JAMA Oncol; 2018 Aug; 4(8):1106-1110. PubMed ID: 29346478
[TBL] [Abstract][Full Text] [Related]
6. Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia.
Dogra R; Bhatia R; Shankar R; Bansal P; Rawal RK
Anticancer Agents Med Chem; 2018; 18(14):1936-1951. PubMed ID: 30360730
[TBL] [Abstract][Full Text] [Related]
7. Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy.
Galkin M; Jonas BA
Core Evid; 2019; 14():3-17. PubMed ID: 31118877
[No Abstract] [Full Text] [Related]
8. Molecular remission and response patterns in patients with mutant-
Stein EM; DiNardo CD; Fathi AT; Pollyea DA; Stone RM; Altman JK; Roboz GJ; Patel MR; Collins R; Flinn IW; Sekeres MA; Stein AS; Kantarjian HM; Levine RL; Vyas P; MacBeth KJ; Tosolini A; VanOostendorp J; Xu Q; Gupta I; Lila T; Risueno A; Yen KE; Wu B; Attar EC; Tallman MS; de Botton S
Blood; 2019 Feb; 133(7):676-687. PubMed ID: 30510081
[TBL] [Abstract][Full Text] [Related]
9. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
DiNardo CD; Schuh AC; Stein EM; Montesinos P; Wei AH; de Botton S; Zeidan AM; Fathi AT; Kantarjian HM; Bennett JM; Frattini MG; Martin-Regueira P; Lersch F; Gong J; Hasan M; Vyas P; Döhner H
Lancet Oncol; 2021 Nov; 22(11):1597-1608. PubMed ID: 34672961
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate dehydrogenase inhibitors in acute myeloid leukemia.
Liu X; Gong Y
Biomark Res; 2019; 7():22. PubMed ID: 31660152
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
[TBL] [Abstract][Full Text] [Related]
12. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH
Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.
DiNardo CD; Venugopal S; Lachowiez C; Takahashi K; Loghavi S; Montalban-Bravo G; Wang X; Carraway H; Sekeres M; Sukkur A; Hammond D; Chien K; Maiti A; Masarova L; Sasaki K; Alvarado Y; Kadia T; Short NJ; Daver N; Borthakur G; Ravandi F; Kantarjian HM; Patel B; Dezern A; Roboz G; Garcia-Manero G
Blood Adv; 2023 Jun; 7(11):2378-2387. PubMed ID: 35973199
[TBL] [Abstract][Full Text] [Related]
14. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
Nassereddine S; Lap CJ; Haroun F; Tabbara I
Ann Hematol; 2017 Dec; 96(12):1983-1991. PubMed ID: 29090344
[TBL] [Abstract][Full Text] [Related]
15. Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment.
Reed DR; Elsarrag RZ; Morris AL; Keng MK
Cancer Manag Res; 2019; 11():8073-8080. PubMed ID: 31564968
[TBL] [Abstract][Full Text] [Related]
16. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
Pollyea DA; Tallman MS; de Botton S; Kantarjian HM; Collins R; Stein AS; Frattini MG; Xu Q; Tosolini A; See WL; MacBeth KJ; Agresta SV; Attar EC; DiNardo CD; Stein EM
Leukemia; 2019 Nov; 33(11):2575-2584. PubMed ID: 30967620
[TBL] [Abstract][Full Text] [Related]
17. Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.
Stein EM
Future Oncol; 2018 Jan; 14(1):23-40. PubMed ID: 29243965
[TBL] [Abstract][Full Text] [Related]
18. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM
Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729
[TBL] [Abstract][Full Text] [Related]
19. Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia.
Myers RA; Wirth S; Williams S; Kiel PJ
J Adv Pract Oncol; 2018; 9(4):435-440. PubMed ID: 30719396
[TBL] [Abstract][Full Text] [Related]
20. Enasidenib and ivosidenib in AML.
Martelli MP; Martino G; Cardinali V; Falini B; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):411-426. PubMed ID: 32955829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
